pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ZIRGAN
drug · small molecule
save

ZIRGAN

updated 3mo ago
by $BLCO Bausch & Lomb Corp🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 2
  • drugganciclovir20 co-mentions · 5 sources
  • tagApproval20 co-mentions · 5 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 8 investigational indications.

targets

DNA polymerase catalytic subunit

all catalysts(0)

nothing on the calendar yet

Trials studying ZIRGAN

  • phase2Study Evaluating the Efficacy and Safety of Artesunaterecruitingn=90
  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • phase2Letermovir for CMV Prevention After Lung Transplantationcompletedn=15
  • phase1Phase 1 Study of GEN2 in Patients With Advanced Solid Tumorsterminatedn=37
  • phase4Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipientscompletedn=70
  • phase2An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomasterminatedn=102
  • phase2Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignanciescompletedn=64
  • phase1Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCterminatedn=26
more trials →

News(0)

no news has mentioned this drug yet

brand
ZIRGAN
trade names
Cymevene, Cytovene, Ganciclovir, Ganzyk-rtu, Virgan, Vitrasert
generic
GANCICLOVIR
MOA
12.1 Mechanism of Action ZIRGAN is an antiviral drug [ see Microbiology (12.4) ] .
indication
1 INDICATIONS AND USAGE ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 26m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?